Lipid evaluation in HIV-1-positive patients treated with protease inhibitors

Antiviral Therapy

Volumn 4, Issue 3, 1999, Pages 163-170

  Schmidt, Hartmut H J ^a   Behrens, Georg ^a   Genschel, Janine ^a   Stoll, Matthias ^a   Dejam, André ^a   Haas, Regina ^a   Manns, Michael P ^a   Schmidt, Reinhold E ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; CHOLESTEROL; INDINAVIR; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN E;

ADULT; ALLELE; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE FREQUENCY; GERMANY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD; CHEMICALLY INDUCED DISORDER; GENETICS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; FEMALE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE;

EID: 0032831091     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.1177/135965359900400305     Document Type: Article

References (5)

1. Dube MP, Johnson DL, Currier JS & Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997; 350:713-714.
2. Eastone JA & Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Annals of Internal Medicine 1997; 127:948.
3. Hengel RL, Watts NB & Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997; 350:1596.
4. Lumpkin MM. Reports of diabetes and hyperglycaemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus. FDA, Public Health Advisor June 11, 1997.
5. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.